anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: ST-segment elevation myocardial infarction (STEMI) presents a serious cardiovascular condition requiring prompt intervention. Dysglycaemia has been identified as a significant risk factor impacting STEMI prognosis. However, limited research has focused on comprehensively examining the association between glucose dynamics during the perioperative period and patient outcomes. This study aims to address this gap by leveraging continuous glucose monitoring (CGM) technology to gain real-time insights into glucose fluctuations and their potential impact on STEMI prognosis.
METHODS AND ANALYSIS: This is a multicentre, prospective, 3-year follow-up cohort study. Between May 2023 and May 2024, 550 eligible STEM patients who underwent percutaneous coronary intervention are expected to be recruited. Using the CGM system, continuous glucose levels will be collected throughout the perioperative phase. Key clinical parameters, including cardiac biomarkers, angiographic findings and major adverse cardiovascular events, will be assessed in relation to glucose profile.
ETHICS AND DISSEMINATION: The study was approved by the Medical Research Ethics Committee of The First Affiliated Hospital of University of Science and Technology of China and will be conducted in accordance with the moral, ethical and scientific principles of the Declaration of Helsinki. Written informed consent will be obtained from all participants before any study-related procedures are implemented. Study results will be disseminated through conferences and peer-reviewed scientific journals.
TRIAL REGISTRATION NUMBER: ChiCTR2300069662.
Agents that reduce the amount of IGFBP-2 and/or IGFBP-5 and that are known to be useful in the treatment of cancer result in increased expression of the protein clusterin. Since clusterin can provide protection against apoptosis, this secondary effect detracts from the efficacy of the therapeutic agent. In overcoming this, the present invention provides a combination of therapeutic agents that is useful in the treatment of cancer. The combination includes an agent that reduces the amount of IGFBP-2 and/or IGFBP-5 and that stimulates expression of clusterin as a secondary effect, and an oligonucleotide that is effective to reduce the amount of clusterin in cancer cells. In some embodiments of the invention, the agent that reduces IGFBP-2 and/or IGFBP-5 is a bispecific antisense species. The oligonucleotide may be an antisense oligonucleotide or an RNAi oligonucleotide.
The invention provides a small non-coding RNA (ribonucleic acid) molecule BSR0601 from Brucella melitensis and an application thereof. Northern blot experiments prove that BSR0601 is related to intracellular survival of Brucella melitensis. By constructing a deletion mutant strain and an overexpression strain of BSR0601, after BSR0601 overexpression is indicated, the survivability of Brucella melitensis under the condition of simulating the pressure of the internal environment of a macrophage is obviously weakened and the survivability of Brucella melitensis in the bodies of mice is also reduced. BSR0601 is also indicated to be related to the toxicity of Brucella melitensis, after BSR0601 overexpression, the toxicity of Brucella melitensis is weakened. Therefore, anti-Brucella melitensis drugs can be prepared by using a BSR0601 overexpression vector as the active ingredient. BSR0601 is bound to play an important role in prevention and treatment of Brucellosis and has an extensive application prospect.
Subjects who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24.
PURPOSE:To obtain the titled safe factor having a high physiological activity, by transplanting homologous tumorous cell or heterologous cell to immunize a mammal, producing the titled factor in blood serum thereof, and separating and collecting the titled factor from the above-mentioned blood serum. CONSTITUTION:A homologous tumorous cell or heterologous cell is inoculated subcutaneously or intraperitoneally to a mammal, e.g. a mouse or rat, and blood is collected therefrom after raising. Blood serum is separated from the collected blood, filtered and sterilized. An antiIg-sepharose column of the same kind as the animal used for producing the above-mentioned blood serum is prepared, and the blood serum is passed through the column by the affinity chromatographic method to remove an Ig fraction in the blood serum. The resultant blood serum is treated by combination of at least one of ion exchange, ultrafiltration or gel filtration to separate and collect the aimed killer T cell differentiation promoting factor.
The invention relates to a preparation method of a double-target double-response nano-drug and an anti-tumor application thereof. Modifying the photosensitizer through tumor vascular targeting peptide and active oxygen responsive bond to obtain amphiphilic macromolecular photosensitizer; modifying the neurotoxic drug by means of a neurotarget peptide and a pH responsive bond to obtain a prodrug; the multifunctional nano-drug is obtained by a nano-precipitation method. The nano-drug realizes the combined treatment of photodynamic anti-vascular and nerve inhibition therapy on tumors by targeting tumor blood vessels and tumor nerves step by step. Aiming at the characteristics of high nerve dominance, easy recurrence and metastasis of advanced tumors which are difficult to operate clinically, and the like, a novel treatment strategy for double inhibition of vascular nerves by utilizing photodynamic activation is provided. The nano system has mild and mature preparation conditions and obvious anti-tumor effect, effectively inhibits metastasis and provides a new idea for clinical tumor treatment. The invention has great development potential and wide clinical application prospect in the aspect of realizing the combined treatment of the neurotropic malignant tumor.
PURPOSE:To obtain the titled product having good appearance without defects, e.g. cracks, by inserting a cylindrical material at a low temperature into a raw material before of after filling a molten raw material into a stick mold, pulling out the cylindrical material, and molding the raw material with a cavity part formed therein. CONSTITUTION:A molten raw material 7 is directly filled into a stick container 1. In the process, the molten raw material 7 is filled into a filling part 5, and a cylindrical material 8 at a lower temperature than the above-mentioned raw material 7 is inserted from a filling port 6 into the raw material 7 in the molten state or the cylindrical material 8 is mounted to the tip of a filling nozzle 9, and the cylindrical material 8 is inserted into the filling part 5. The molten raw material 7 is extruded through an extrusion outlet (9a) at the tip of the nozzle 9, and filled in the filling part 5. After solidifying the periphery of the cylindrical material 8, the cylindrical material 8 is pulled out. The molten raw material 7 is completely solidified with a cavity part 11 formed therein, and the internal stress produced at that time is concentrated on the above-mentioned cavity part 11 to prevent the formation of sink or crack, etc.
Risk Summary

The 10 mL Cisatracurium Besylate Injection multiple-dose vials contains the preservative benzyl alcohol. Therefore, if Cisatracurium Besylate Injection is needed during lactation, consider using a benzyl alcohol-free formulation (i.e., 5 mL and 20 mL Cisatracurium Besylate Injection single-dose vials). Because benzyl alcohol is rapidly metabolized by a lactating woman, benzyl alcohol exposure in the breastfed infant is unlikely. However, adverse reactions have occurred in premature neonates and low birth weight infants who received intravenously administered benzyl alcohol-containing drugs [see Contraindications (4), Warnings and Precautions (5.2), and Use in Specific Populations (8.4)].

There are no data on the presence of cisatracurium besylate in human milk, the effects on the breastfed child, or the effects on milk production.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for Cisatracurium Besylate Injection and any potential adverse effects on the breastfed child from Cisatracurium Besylate Injection or from the underlying maternal condition.
BACKGROUND/AIMS: We assessed the associations between retinopathy of prematurity (ROP) and continuous measurements of oxygen saturation (SpO2), and developed a risk prediction model for severe ROP using birth data and SpO2 data.
METHODS: This retrospective study included infants who were born before 30 weeks of gestation between August 2009 and January 2019 and who were screened for ROP at a single hospital in Japan. We extracted data on birth weight (BW), birth length, gestational age (GA) and minute-by-minute SpO2 during the first 20 days from the medical records. We defined four SpO2 variables using sequential measurements. Multivariate logistic regression was used to develop a model that combined birth data and SpO2 data to predict treatment-requiring ROP (TR-ROP). The model's performance was evaluated using the area under the receiver operating characteristic curve (AUC).
RESULTS: Among 350 infants, 83 (23.7%) required ROP treatment. The SpO2 variables in infants with TR-ROP differed significantly from those with non-TR-ROP. The average SpO2 and high SpO2 showed strong associations with GA (r=0.73 and r=0.70, respectively). The model incorporating birth data and the four SpO2 variables demonstrated good discriminative ability (AUC=0.83), but it did not outperform the model incorporating BW and GA (AUC=0.82).
CONCLUSION: Data obtained by continuous SpO2 monitoring demonstrated valuable associations with severe ROP, as well as with GA. Differences in the distribution of average SpO2 and high SpO2 between infants with TR-ROP and non-TR-ROP could be used to establish efficient cut-off values for risk determination.
Thoracic aortic dissection (TAD) is a critical clinical condition partly due to the rupture of aortic aneurysm. Mostly, surgical treatment can reduce the symptoms and extend life span of patients with thoracic aortic aneurysm and dissection (TAAD). However, mortality of TAAD remains high because of the huge blood lost from the aorta. Sporadic TAAD was considered to be a server consequence of hypertension, though most patients with hypertension won't have TAAD as their final outcomes. Previous studies have revealed the associations between genetic abnormalities and familial TAAD, and genetic tests have applied to assist the diagnosis of certain TAAD. Therefore, the potentially genetic effects on sporadic TAAD are explored by researchers to understand the possible mechanisms leading to sporadic TAAD and to establish new clinical approaches to prevent TAAD-caused adverse clinical outcomes. This study is intended to collect the gene information in sporadic TAAD patients and to explore the relationship between genetic variation and the incidence of sporadic TAAD for further study.
BACKGROUND: Acute abdominal pain (AAP) is a major driver for capacity-use in emergency departments (EDs) worldwide. Yet, the health care utilization of patients with AAP before and after the ED remains unclear. The primary objective of this study was to describe adult patients presenting to the ED with AAP and their outpatient care (OC) use before and after the ED. Secondary objectives included description of hospitalization rates, in-hospital mortality, ED re-visits, and exploration of potential risk factors for hospitalization and ED re-visits.
METHODS: For the analysis, we combined routine hospital data from patients who visited 15 EDs in Germany in 2016 with their statutory health insurance OC claims data from 2014 to 2017. Adult patients were included based on a chief complaint or an ED diagnosis indicating unspecific AAP or the Manchester Triage System indicator "Abdominal pain in adults". Baseline characteristics, ED diagnosis, frequency and reason of hospitalization, frequency and type of prior-OC (prOC) use up to 3 days before and of post-OC use up to 30 days after the ED visit.
MAIN RESULTS: We identified 28,085 adults aged ≥ 20 years with AAP. 39.8% were hospitalized, 33.9% sought prOC before the ED visit (48.6% of them were hospitalized) and 62.7% sought post-OC up to 30 days after the ED visit. Hospitalization was significantly more likely for elderly patients (aged 65 and above vs. younger; adjusted OR 3.05 [95% CI 2.87; 3.25]), prOC users (1.71 [1.61; 1.90]) and men (1.44 [1.37; 1.52]). In-hospital mortality rate was 3.1% overall. Re-visiting the ED within 30 days was more likely for elderly patients (1.32 [1.13; 1.55) and less likely for those with prOC use (0.37 [0.31; 0.44]).
CONCLUSIONS: prOC use was associated with more frequent hospitalizations but fewer ED re-visits. ED visits by prOC patients without subsequent hospitalization may indicate difficulties of OC resources to meet the complex diagnostic requirements and expectations of this patient population. Fewer ED re-visits in prOC users indicate effective care in this subgroup.
Macronutrients in breast milk can be affected by various factors. The mothers will be taken in the first 24 hours after birth and their nutritional habits, socio-demographic characteristics, anthropometric characteristics of the mother, body mass index will be examined and newborn characteristics will be taken. 2 ml sample from colostrum will be analyzed with milk analyzer instrument. The mothers will be re-checked on the 5th day and their anthropometric properties will be obtained. The same procedure will be repeated on the 15th day after childbirth. At each control, the mother's last 24-hour feeding status will be taken and the nutritional values consumed by "BeBis" program will be examined.
The invention belongs to the field of materials, and relates to a macromolecular contrast agent, a preparation method and application thereof. The invention has the advantages that: (1) structural adjustability. The proportion of PEI to CD in the main structure PEI-CD can be regulated to regulate the content of CD, so that the number of sites capable of reacting with AD is regulated. The controllability of the ratio of the PEG to the PLL of the side chain structure adjusts the density of gadolinium and the size of the overall structure. (2) convenience of modification of targeting groups. The bio-orthogonal reaction is environment-friendly and has high reaction speed. The invention utilizes bio-orthogonal reaction to modify the targeting group on the polymer, and has simple reaction.
The study will include three study visits over a 90 days period, with study visit one (SV1) occurring at day 0. SV2 conducted at day 45, and SV3 conducted at day 90. The participant will be provided with L/Z supplements which contains 6 mg of lutein and 4 mg of zeaxanthin and will be asked to consume the given items five days per week. After the 45-day intake period, the participants will return to the lab for SV2 and then be given a new 45-day supply of items to consume until the end of the 90 day test period (SV3).
OBJECTIVES: This study assessed the validity of nomograms for predicting malignant transformation (MT) among patients with oral leukoplakia (OL) and oral lichen planus (OLP).
MATERIALS AND METHODS: Two nomograms were identified following a systematic search. Variables to interrogate both nomograms were obtained for a retrospective OL/OLP cohort. Then, the nomograms were applied to estimate MT probabilities twice and their average was used to calculate the discriminatory performance, calibration, and potential net benefit of the models. Subgroup analyses were performed for patients with OL, OLP, and oral epithelial dysplasia.
RESULTS: Predicted probabilities were mostly significantly higher among OL/OLP patients who developed MT compared to those who did not (p = <0.001-0.034). AUC values and Brier scores of the nomograms were 0.644-0.844 and 0.040-0.088 among OL patients and 0.580-0.743 and 0.008-0.072 among OLP patients. Decision curve analysis suggested that the nomograms had some net benefit for risk stratification. However, the models did not best binary dysplasia grading in discriminatory validity and net benefit among patients with OL and oral epithelial dysplasia.
CONCLUSION: Nomograms for predicting MT may have satisfactory validity among patients with OL than OLP, but they do not outperform binary dysplasia grading in risk stratification of OL.
PROBLEM TO BE SOLVED: To provide systems and methods for management of medical coding.SOLUTION: A device may receive information that identifies a first medical term and may determine whether the first medical term corresponds to a first medical code, which may be a medical code previously input by a first user in association with a second medical term. Or, the first medical code may be included in a dictionary. The device may determine a valid code corresponding to the first medical term based on determining whether the first medical term corresponds to the first medical code. The valid code may be determined based on the first medical code when the first medical term corresponds to the first medical code. The valid code may be determined based on a second medical code, input by a second user, when the first medical term does not correspond to the first medical code. The device may provide information that identifies the valid code.SELECTED DRAWING: Figure 4
Abnormal phosphorylation of the microtubule-binding protein tau in the brain is a key pathological marker for Alzheimer's disease and additional neurodegenerative tauopathies. However, how hyperphosphorylated tau causes cellular dysfunction or death that underlies neurodegeneration remains an unsolved question critical for the understanding of disease mechanism and the design of efficacious drugs. Using a recombinant hyperphosphorylated tau protein (p-tau) synthesized by the PIMAX approach, we examined how cells responded to the cytotoxic tau and explored means to enhance cellular resistance to tau attack. Upon p-tau uptake, the intracellular calcium levels rose promptly. Gene expression analyses revealed that p-tau potently triggered endoplasmic reticulum (ER) stress, unfolded protein response (UPR), ER stress-associated apoptosis, and pro-inflammation in cells. Proteomics studies showed that p-tau diminished heme oxygenase-1 (HO-1), an ER stress-associated anti-inflammation and anti-oxidative stress regulator, while stimulated the accumulation of MIOS and other proteins. p-Tau-induced ER stress-associated apoptosis and pro-inflammation are ameliorated by apomorphine, a brain-permeable prescription drug widely used to treat Parkinson's disease symptoms, and by overexpression of HO-1. Our results reveal probable cellular functions targeted by hyperphosphorylated tau. Some of these dysfunctions and stress responses have been linked to neurodegeneration in Alzheimer's disease. The observations that the ill effects of p-tau can be mitigated by a small compound and by overexpressing HO-1 that is otherwise diminished in the treated cells inform new directions of Alzheimer's disease drug discovery.
A system intelligently implements communication between at least one patient and at least one medical practitioner, preferably using two-way natural language conversation. The patient discloses or is prompted to disclose relevant medical condition and background, daily routines, that a medical practitioner would want to diagnose and prescribe for a present medical condition. The conversation is content-based routed in real-time to multiple potential medical responders, preferably including a machine learning (ML) based software agent, as well as human responders having various levels of medical expertise. Such routing advantageously minimizes volume of irrelevant information sent to a responder, and also reduces the cost of information responded to by the most appropriate responder. Over time, the ML-based software agent improves performance by using training data from patient-system communications, and/or via active learning methods. Compartmentalization of patient information promotes patient privacy policies while maximizing relevance of patient-system
The participants received antioxidant-depleted snacks every day during 21 days of moderate altitude training (2300 meters above sea level). The snack included milkshake, and other milk-based drinks, biscuits (both sweet and salty), white chocolate.
PURPOSE: An immunosuppression containing mycophenolate or derivative thereof and cyclosporine is provided to sample administration effect with a case of administering mycophenolate tablets and cyclosporine tablets. CONSTITUTION: A composite tablet contains cyclosporine and mycophenolate. The cyclosporine is cyclosporine A. The mycophenolate is mycophenolate or derivative thereof. An immunosuppressant contains 3-9 weight ratio of cyclosporine A, 29-87 weight ratio of mycophenolate mofetil, 10-30 weight ratio of hydroxypropyl methyl cellulose, 5-25 weight ratio of avicel PH101, and 1 weight ratio of stearate magnesium salt. The mycophenolate mofetil is denoted by (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. The hydroxypropyl methyl ceullose is a water swellable polymer.
This project aims to improve the treatment of pediatric patients infected with COVID-19. Interferon has antiviral property and is approved to be used in treatment in hepatitis B and hepatitis C virus infections. Interferon α2b, β1a and lambda are under evaluation in clinical trials for the treatment of COVID-19 in adult. As upper respiratory tract infection is the dominant characteristic of most infected children, topical treatment may be a better way to increase the safety and efficacy than oral or intravenous medication. This study aims to obtain essential data regarding the efficacy and safety of inhaled Interferon α2b in children with mild to moderate COVID-19 infection. Subjects will be enrolled with COVID-19 infection diagnoses by ORF1ab gene and N gene PCR test. Standard evaluation process will be applied to identify mild and moderate patients. Patients will be randomized into interferon group and non-interferon group. Patients in interferon group will receive inhalation treatment within the first five days since the symptom onset. Patients will receive daily PCR test. Cycle threshold (Ct) values over 35 is considered as de-isolation criterion. Days requiring isolation (from symptom onset to de-isolation time point) is the major index to evaluate efficacy. Clinical manifestations and test results from clinical recording system will be collected to evaluate the side effects.